» Articles » PMID: 6116757

Animal Modelling of Human Polymorphic Drug Oxidation--the Metabolism of Debrisoquine and Phenacetin in Rat Inbred Strains

Overview
Specialties Pharmacology
Pharmacy
Date 1981 Mar 1
PMID 6116757
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

The metabolism of debrisoquine (5 mg kg-1 orally) was investigated in females of 7 strains of rat. Two major metabolic pathways, those of 4- and 6-hydroxylation were found to be polymorphic. The DA strain eliminated in urine only 7-10% of the dose as 4-hydroxy-debrisoquine together with 31-55% debrisoquine while the corresponding values for the Lewis strain were 44-55% and 11-17% respectively. Accordingly, DA and Lewis rats were proposed as models for the human PM (poor metabolizer) and EM (extensive metabolizer) drug oxidation phenotypes. To further test this model, DA and Lewis rats were given phenacetin (200 mg kg-1 orally). This underwent O-de-ethylation to paracetamol (52-55%) and aromatic 2-hydroxylation (7-8%) in Lewis rats. The corresponding findings in DA rats were 35-40% O-de-ethylation and 12-13% 2-hydroxylation. It is suggested that, with respect to both debrisoquine and phenacetin, Lewis and DA inbred rat strains afford a model of oxidative drug metabolism for the human EM and PM phenotypes respectively.

Citing Articles

Functional characterization of a first avian cytochrome P450 of the CYP2D subfamily (CYP2D49).

Cai H, Jiang J, Yang Q, Chen Q, Deng Y PLoS One. 2012; 7(6):e38395.

PMID: 22675558 PMC: 3366968. DOI: 10.1371/journal.pone.0038395.


The role of monoamines in the changes in body temperature induced by 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and its derivatives.

Docherty J, Green A Br J Pharmacol. 2010; 160(5):1029-44.

PMID: 20590597 PMC: 2936013. DOI: 10.1111/j.1476-5381.2010.00722.x.


The hyperthermic and neurotoxic effects of 'Ecstasy' (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype.

Colado M, Williams J, Green A Br J Pharmacol. 1995; 115(7):1281-9.

PMID: 7582557 PMC: 1908797. DOI: 10.1111/j.1476-5381.1995.tb15037.x.


Characterization of a human liver cytochrome P-450 involved in the oxidation of debrisoquine and other drugs by using antibodies raised to the analogous rat enzyme.

Distlerath L, Guengerich F Proc Natl Acad Sci U S A. 1984; 81(23):7348-52.

PMID: 6594694 PMC: 392143. DOI: 10.1073/pnas.81.23.7348.


Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man.

Kupfer A, Preisig R Eur J Clin Pharmacol. 1984; 26(6):753-9.

PMID: 6489416 DOI: 10.1007/BF00541938.